{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:53:20Z","timestamp":1720659200417},"reference-count":36,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.2169\/internalmedicine.2513-18","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:26:06Z","timestamp":1555453566000},"page":"2159-2166","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)"],"prefix":"10.2169","volume":"58","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"},{"name":"Department of Clinical Studies, Radiation Effects Research Foundation, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Tochigi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakaike","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Mashiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481-492, 1977.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 81: 25342537, 1984.","DOI":"10.1073\/pnas.81.8.2534"},{"key":"3","unstructured":"3. Tajima K, Kuroishi T. Estimation of rate of incidence of ATL among ATLV (HTLV-I) carriers in Kyushu, Japan. Jpn J Clin Oncol 15: 423-430, 1985."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"5","unstructured":"5. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001."},{"key":"6","unstructured":"6. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007."},{"key":"7","unstructured":"7. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27: 453-459, 2009."},{"key":"8","unstructured":"8. Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia\/lymphoma: past, present, and future. Eur J Haematol 80: 185-196, 2008."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop 50: 9-25, 2010.","DOI":"10.3960\/jslrt.50.9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tsukasaki K, Tobinai K. Clinical trials and treatment of ATL. Leuk Res Treatment 2012: 101754, 2012.","DOI":"10.1155\/2012\/101754"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma. Leukemia 19: 829-834, 2005.","DOI":"10.1038\/sj.leu.2403682"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma. Blood 105: 4143-4145, 2005.","DOI":"10.1182\/blood-2004-11-4193"},{"key":"13","unstructured":"13. Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia\/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14: 702-708, 2008."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116: 1369-1376, 2010.","DOI":"10.1182\/blood-2009-10-247510"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 120: 1734-1741, 2012.","DOI":"10.1182\/blood-2012-03-414490"},{"key":"16","unstructured":"16. Yamada Y, Atogami S, Hasegawa H, et al. Nationwide survey of adult T-cell leukemia\/lymphoma (ATL) in Japan. Rinsho Ketsueki (Jpn J Clin Hematol) 52: 1765-1771, 2011 (in Japanese, Abstaract in English)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kawano N, Yoshida S, Kuriyama T, et al. Clinical features and treatment outcomes of 81 patients with aggressive type adult T-cell leukemia-lymphoma at a single institution over a 7-year period (2006-2012). Intern Med 54: 1489-1498, 2015.","DOI":"10.2169\/internalmedicine.54.1953"},{"key":"18","unstructured":"18. Taniguchi H, Imaizumi Y, Makiyama J, et al. Outcome of patients with relapsed\/refractory adult T-cell leukemia-lymphoma after salvage therapy. Rinsho Ketsueki (Jpn J Clin Hematol) 54: 21592166, 2013 (in Japanese, Abstract in English)."},{"key":"19","unstructured":"19. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30: 837842, 2012."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Jo T, Ishida T, Takemoto S, et al. Randomoized phase II study of mogamulizumab (KW-0761) plus mLSG 15 versus mLSG 15 alone for newly diagnosed aggressive ATL. J Clin Oncol 31: 8506, 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.8506"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma. Cancer Sci 104: 647-650, 2013.","DOI":"10.1111\/cas.12116"},{"key":"22","unstructured":"22. Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol 41: 239-244, 2014."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kawano N, Kuriyama T, Sonoda KH, et al. Clinical impact of a humanized CCR4 antibody (mogamulizumab) in 14 patients with aggressive adult T-cell leukemia-lymphoma treated at a single institution during a three-year period (2012-2014). Intern Med 55: 1439-1445, 2016.","DOI":"10.2169\/internalmedicine.55.6312"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sekine M, Kubuki Y, Kameda T, et al. Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice. Eur J Haematol 98: 501-507, 2017.","DOI":"10.1111\/ejh.12863"},{"key":"25","unstructured":"25. Ishitsuka K, Yurimoto S, Kawamura K, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol 106: 522-532, 2017."},{"key":"26","unstructured":"26. Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci 108: 2022-2029, 2017."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64: 2127-2133, 2004.","DOI":"10.1158\/0008-5472.CAN-03-2068"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 110: 17945-17950, 2013.","DOI":"10.1073\/pnas.1316796110"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nakagawa M, Schmitz R, Xiao W, et al. Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma. J Exp Med 211: 2497-2505, 2014.","DOI":"10.1084\/jem.20140987"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yoshida N, Miyoshi H, Kato T, et al. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis. J Pathol 238: 621-626, 2016.","DOI":"10.1002\/path.4699"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood 132: 758-761, 2018.","DOI":"10.1182\/blood-2018-02-835991"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood 128: 1374-1381, 2016.","DOI":"10.1182\/blood-2016-02-698936"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Asano N, Miyoshi H, Kato T, et al. Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia\/lymphoma. Histopathology 72: 945-954, 2018.","DOI":"10.1111\/his.13461"},{"key":"34","unstructured":"34. Kataoka K, Nagata Y, Kitanaka A, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet 47: 1304-1315, 2015."},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Umino A, Nakagawa M, Utsunomiya A, et al. Clonal evolution of adult T-cell leukemia\/lymphoma takes place in the lymph nodes. Blood 117: 5473-5478, 2011.","DOI":"10.1182\/blood-2010-12-327791"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ueda R. Clinical application of anti-CCR4 monoclonal antibody. Oncology 89 (Suppl 1): 16-21, 2015.","DOI":"10.1159\/000431059"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/15\/58_2513-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T15:12:26Z","timestamp":1607267546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/15\/58_2513-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2513-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}